CIML-NK Cells to Treat Neuroblastoma in Relapsed or Refractory Patients

Is this trial a fit for you?

A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.

What this trial studies

This is a Phase 2 interventional study evaluating the safety and potential benefit of infusing CIML-NK cells generated from donor cells in combination with dinutuximab-based therapy for relapsed or refractory neuroblastoma. Eligible participants are aged 1 to 39 with high-risk, histologically confirmed neuroblastoma and evaluable disease. The trial analyzes whether CIML-NK cells can be safely infused and whether they may improve responses when used alongside standard dinutuximab-containing regimens. No collaborators are listed beyond the lead site, Cincinnati Children’s Hospital Medical Center. The study will be conducted at a single location in Cincinnati, Ohio.

Why it matters

Who can join: the full rules

Inclusion Criteria:

* Age 1-39 years at the time of study enrollment
* With diagnosis of neuroblastoma with histologic verification
* Classified as high-risk neuroblastoma as defined by Children's Oncology Group (COG) risk classification, including patients initially classified as low or intermediate risk at diagnosis with subsequent reclassification as high-risk disease
* With relapsed or refractory disease, including at least one of the following:

  1. Recurrent disease at any time after completion of frontline therapy
  2. Progressive disease at any time following standard induction therapy
  3. Primary resistant or refractory disease defined by failure to achieve a complete response by International Neuroblastoma Response Criteria (INRC) after at least four cycles of standard, multidrug induction chemotherapy on or according to a high-risk neuroblastoma protocol
* Patients must have evaluable disease documented within four weeks of study enrollment. Evaluable disease must include at least one of the following:

  1. Measurable tumor (\>10 mm in at least one dimension) on MRI or CT scan that is either MIBG, FDG or 68Ga-DOTATATE avid
  2. One or more MIBG, FDG, or 68Ga-DOTATATE avid bone lesion
  3. Microscopic marrow metastasis based on routine morphology and/or immunohistochemistry in at least one sample from bilateral aspirates and biopsies at the time of study enrollment.
* With performance level of \>50% on Lansky (\<16 years) or Karnofsky (\>16 years) scales. Patients who are wheelchair bound due to paralysis will be considered ambulatory when assessing their performance score.
* Adequate baseline cardiac and pulmonary function including a left ventricular ejection fraction (LVEF) \>50% by echocardiogram and pulse oximetry \>92% on room air documented within four weeks of study enrollment.
* Adequate baseline hematologic function: peripheral absolute neutrophil count (ANC) ≥500/µL, with no receipt of long-acting myeloid growth factors within 14 days or short-acting myeloid growth factors within 7 days of study entry, and a platelet count ≥50,000/µL, with patients required to be transfusion independent for at least 7 days, unless cytopenias are related to marrow metastasis as defined above.
* With available haploidentical related donors.

Exclusion Criteria:

* Infectious disease: Active, uncontrolled infection or received a live vaccine within 30 days prior to study enrollment.
* Cardiac function: LVEF \<50% by echocardiogram, serious uncontrolled cardiac arrhythmias, or history of myocarditis or congestive heart failure (New York Heart Association Functional Classification III or IV)
* Pulmonary function: Active interstitial lung disease (ILD)/pneumonitis or history of ILD/pneumonitis requiring systemic corticosteroid treatment.
* Renal function: Glomerular Function Rate (GFR) \<50 mL/min/1.73 m2 as measured by cystatin C or NM GFR
* Hepatic function: Total bilirubin \>5 mg/dL, AST and ALT \>10 times the upper limit of normal
* Concomitant medications: receiving \>0.5 mg/kg prednisone equivalent daily
* Receipt of any concomitant investigational treatments within 30 days at the time of the infusion of the IP. These investigational treatments include drugs, biologics, or devices that are still under investigation in clinical trials or research settings. The use of such agents may confound study results or pose additional safety risks
* Known allergy or hypersensitivity reaction to IL-2 injections
* Pregnant or breastfeeding women

Where it's running

• Cincinnati Children's Hospital Medical Center
  Cincinnati, Ohio, United States Recruiting

Study contacts

• Principal investigator: Christopher Dandoy, MD, MS — Children's Hospital Medical Center, Cincinnati
• Study coordinator: Caitlin Cottrell, BSN, RN
• Email: Caitlin.cottrell@cchmc.org
• Phone: 513-803-7039

Similar studies

Other studies for the same condition or treatment. Recruiting studies are listed first.

• Neuroblastoma patients' genomic and biological profile study

  This multicenter, prospective study tests profiles from blood, tumor tissue, and bone marrow to understand neuroblastoma in diagnosed, relapsed, or refractory patients.

  Recruiting at 35 sites Istituto Giannina Gaslini · Ancona and 34 other locations · NCT07881172

• Becotatug Vedotin for EGFR-positive relapsed, refractory, or metastatic pediatric solid tumors

  This trial will test Becotatug Vedotin, an EGFR-targeted antibody-drug conjugate, to see if it is safe and helps children aged 2–18 with EGFR-positive relapsed, refractory, or metastatic solid tumors.

  Recruiting Phase 1 Sun Yat-sen University · Guangzhou, Guangdong · NCT07584499

• Tracking tumor DNA over time in neuroblastoma

  This project tests whether regular blood tests measuring circulating tumor DNA and molecular residual disease can track disease status and detect relapse earlier in children with neuroblastoma.

  Recruiting Sun Yat-sen University · Guangzhou, Guangdong · NCT07516678

• Anti-GD2-800CW imaging to highlight neuroblastoma during surgery

  This trial will test whether a fluorescent antibody called anti-GD2-800CW can safely help surgeons see and remove neuroblastoma in children ages 1 to 18.

  Recruiting Phase 1/2 Princess Maxima Center for Pediatric Oncology · Utrecht · NCT07399821

• B7-H3 CAR T cells for relapsed or refractory solid tumors in children and young adults

  This study tests a new B7-H3 CAR T cell therapy to see if it is safe and can help kids and young adults whose solid tumors have come back or stopped responding to standard treatments.

  Recruiting Phase 1 Dana-Farber Cancer Institute · Boston, Massachusetts · NCT07358260

• NET- and somatostatin-targeted PET/SPECT imaging to find and stage neuroblastoma and pheochromocytoma/paraganglioma

  This study will try different PET and SPECT tracers to see if they can accurately find and stage tumors in children and adults with neuroblastoma or pheochromocytoma/paraganglioma.

  Recruiting Nanjing First Hospital, Nanjing Medical University · Nanjing, Jiangsu · NCT07195500

How to take part

1. Review the eligibility criteria above with your treating physician.
2. Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
3. Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.